Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD

Saved in:

Bibliographic Details
Main Authors:	Masayuki Yamanouchi, Yuki Oba, Hisashi Kamido, Masatoshi Yoshimoto, Yusuke Yoshimura, Hisashi Sugimoto, Shigekazu Kurihara, Akinari Sekine, Tatsuya Suwabe, Naoki Sawa, Takehiko Wada, Kengo Furuichi, Takashi Wada, Yoshifumi Ubara
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	Kidney International Reports
Subjects:	chronic kidney disease eGFR slope finerenone nonsteroidal mineralocorticoid receptor (MR) antagonist real-world study type 2 diabetes mellitus
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024925002256
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trajectory of GFR Decline and Fluctuation in Albuminuria Leading to End-Stage Kidney Disease in Patients With Biopsy-Confirmed Diabetic Kidney Disease
by: Masayuki Yamanouchi, et al.
Published: (2024-02-01)

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
by: Hongxuan Fan, et al.
Published: (2025-08-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Evaluation of Light Chain Removal Rates in Blood Purification Therapy for Light Chain Cast Nephropathy
by: Hisashi Kamido, et al.
Published: (2025-05-01)

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings
by: Cezary Kubuj, et al.
Published: (2025-07-01)

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01)

Dialysis-related amyloidosis: a review from case series
by: Yoshifumi Ubara, et al.
Published: (2025-02-01)

Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study
by: Yu Li, et al.
Published: (2025-07-01)

Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
by: Jingying Zhou, et al.
Published: (2024-12-01)

Proteinuria reduction by and safety of finerenone in Chinese patients with CKD without diabetes: a real-world retrospective study
by: Guangting Cong, et al.
Published: (2025-08-01)

The Retinal Vasculature and Risk of Age-Related GFR Decline — The Renal Iohexol Clearance Survey
by: Silje Småbrekke, et al.
Published: (2025-05-01)

Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy
by: Shu J, et al.
Published: (2025-02-01)

Efficacy of finerenone in reducing heart failure outcomes in patients with history of heart failure: A meta-analysis of randomized controlled trials
by: Vikash Jaiswal, et al.
Published: (2024-12-01)

Feasibility of replacing 99mTc‐DTPA GFR measurements with eGFR from cystatin C in individuals with spinal cord injuries
by: Tatiana Kristensen, et al.
Published: (2025-05-01)

Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study
by: Yiming Wu, et al.
Published: (2025-06-01)

Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing pathological features and kidney prognosis
by: Naoki Sawa, et al.
Published: (2025-03-01)

Brachial-ankle pulse wave velocity predicts liver volume in patients with autosomal dominant polycystic kidney disease
by: Wasako Tato, et al.
Published: (2025-01-01)

Effect and Safety of Finerenone in Patients with IgA Nephropathy
by: Guo Y, et al.
Published: (2025-07-01)

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone
by: I. S. Khalimov, et al.
Published: (2025-01-01)

Association of finerenone with prognosis and safety in diabetic kidney disease patients: an undated meta-analysis based on four RCTs
by: Zixuan Zhang, et al.
Published: (2025-07-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry
by: Gonzalo Luis Alonso Salinas, et al.
Published: (2025-08-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
by: Sara W. Quist, et al.
Published: (2023-11-01)

The Discrepancy Between Estimated GFR Cystatin C and Estimated GFR Creatinine at 3 Months After Hospitalization and Long-Term Adverse Outcomes
by: Yumeng Wen, et al.
Published: (2025-06-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

A meta-analysis of the effects of finerenone on cardio-renal outcomes in patients with type 2 diabetes mellitus or chronic kidney disease
by: Liu Jing, et al.
Published: (2025-06-01)

Case of obesity-related glomerulopathy treated by pronounced weight loss by diet and exercise
by: Hisashi Sugimoto, et al.
Published: (2025-03-01)

Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery
by: Kerry L. Horne, et al.
Published: (2025-08-01)

Efficacy and safety of finerenone in individuals with type 2 diabetes mellitus complicated by diabetic kidney disease: A retrospective observational study
by: Yuji Kawaguchi, et al.
Published: (2024-12-01)

Stability indicating RP-HPLC method for estimation of finerenone and its related substances in new dosage form
by: Aya A. Marie, et al.
Published: (2025-06-01)

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
by: Duc Tin Tran, et al.
Published: (2024-11-01)

A comprehensive examination and analysis of the effectiveness and safety of finerenone for the treatment of diabetic kidney disease: a systematic review and meta-analysis
by: Jianyu Chen, et al.
Published: (2024-12-01)

Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
by: Hiroyuki Ueda, et al.
Published: (2025-07-01)

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes
by: Gerasimos Filippatos, et al.
Published: (2025-02-01)

Estimated Glomerular Filtration Rate (eGFR) as an In-Hospital Mortality Predictor in Acute Coronary Syndrome Patients in ICCU
by: Esthika Dewiasty, et al.
Published: (2016-12-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)